Lindblad, O <br/><br/>
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.  [electronic resource] 

 -  Oncogene  09 2016 
 - 5119-31 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/onc.2016.41  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Apoptosis--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Drug Resistance, Neoplasm--genetics<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Mice<br/>Morpholines--administration & dosage<br/>Mutation<br/>Niacinamide--administration & dosage<br/>Phenylurea Compounds--administration & dosage<br/>Phosphatidylinositol 3-Kinases--genetics<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Protein Kinase Inhibitors--administration & dosage<br/>Signal Transduction--drug effects<br/>Sorafenib<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Triazines--administration & dosage<br/>Xenograft Model Antitumor Assays<br/>fms-Like Tyrosine Kinase 3--genetics